SION — Sionna Therapeutics, Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 2036042 ·
Last close
$6.25
Market Cap
$282.19M
52W High
$54.97
52W Low
$4.01
ADV30
3,248,997
Next earnings
2026-11-05
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 0 -32,470,000 -29,886,000 283,249,000 63,322,000 17,474,000
Mar 2026 0 -29,599,000 -26,779,000 305,039,000 63,324,000 16,831,000
Dec 2025 0 -23,612,000 -20,440,000 325,953,000 58,451,000 19,120,000
Sep 2025 0 -23,805,000 -20,278,000 339,270,000 50,831,000 17,602,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-75,916,000
Investing CF
$91,979,000
Financing CF
$6,275,000
CapEx
$-377,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.18
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-313,019,000
Inventory
Receivables
ST Investments
$147,709,000
EBIT TTM
$-109,486,000
Pretax Income TTM
$-97,383,000
Interest Exp TTM
Analysts
10

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -88,982,000 -75,268,000 325,953,000 19,120,000 -66,297,000
Dec 2024 0 -70,556,000 -61,688,000 185,752,000 349,465,000 -52,787,000
Dec 2023 0 -50,333,000 -47,263,000 51,945,000 166,826,000 -43,699,000
Dec 2022 0 -41,372,000 -40,240,000 87,369,000 157,293,000 -36,068,000

TTM Snapshot

Revenues TTM
$2,566,000
NetIncome TTM
$-8,552,000
OpCashFlow TTM
$0
Assets (Latest)
$185,752,000
Forward EPS
$-2.53

Max Pain — expiry 2027-01-15

max pain strike: $7.50 · spot: $6.25 · call oi: 452 · put oi: 702
Expected Move to 2027-01-15: ±$2.90 (46.40%) — implied range $3.35$9.15 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ELDN Eledon Pharmaceuticals, Inc. $281.98M $3.47
CAMP Camp4 Therapeutics Corp $279.25M $4.45
ALXO ALX ONCOLOGY HOLDINGS INC $276.55M $2.00
EBS Emergent BioSolutions Inc. $289.18M $5.64
WHWK Whitehawk Therapeutics, Inc. $289.61M $5.08

News headlines (Yahoo Finance, 1h cache)

Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep?
2026-08-13 09:11 · Yahoo
Sionna Therapeutics (SION) Is Down 86.8% After Halting SION-719 And Refocusing Its CF Pipeline – Has The Bull Case Changed?
2026-08-13 05:13 · Yahoo
Sionna Therapeutics (SION) Stock Still Looks Cheap After The 90% Fall
2026-08-12 10:12 · Yahoo
Sionna Therapeutics stock falls 92% after SION-719 trial failure
2026-08-11 13:11 · Yahoo
Sionna Therapeutics (SION) Halts Lead Cystic Fibrosis Drug After Phase 2 Failure
2026-08-11 08:12 · Yahoo
SION Stock On Track For Worst Day Ever After 90% Drop — What’s Driving The Selloff?
2026-08-10 17:18 · Yahoo
Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low
2026-08-10 19:14 · Yahoo
Sionna Therapeutics shares collapse 92% after cystic fibrosis trial misses key endpoint
2026-08-10 12:48 · Yahoo
Sionna cystic fibrosis drug fails key trial, removing threat to Vertex
2026-08-10 12:22 · Yahoo
Why Vertex Pharma Popped, As A Key Rival Plummeted 92%
2026-08-10 20:04 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.